Kriya Licenses Next Generation Complement-Targeted Gene Therapies for the Treatment of Geographic Atrophy and Other Ocular Diseases

REDWOOD CITY, Calif. and RESEARCH TRIANGLE PARK, N.C., January 26, 2022 — Kriya Ther­a­peu­tics, Inc., a fully integrated company pioneering novel tech­nolo­gies and ther­a­peu­tics in gene therapy, today announced an exclusive agreement with the Medical University of South Carolina (MUSC) Foundation for Research Development to license next generation complement-targeted gene therapies for the treatment of geographic atrophy and other ocular diseases.

Geographic atrophy, also known as atrophic age-related macular degen­er­a­tion (AMD), is an advanced form of AMD, a progressive retinal disease affecting millions of adults worldwide. Patients with geographic atrophy experience irre­versible loss of vision with significant impact on quality of life due to the chronic and progressive nature of the disease. There are currently no FDA-approved treatments available for geographic atrophy.

“This partnership highlights the broad potential of Kriya’s technology and R&D platforms to drive innovation in diseases with established biology, and furthers our mission of developing trans­for­ma­tive gene therapies for diseases with high unmet need,” said Theresa Heah, M.D., M.B.A., President and Chief Medical Officer of Kriya’s oph­thal­mol­o­gy division. ​“We believe that complement hyper­ac­tiv­i­ty is a clinically validated target implicated in the patho­gen­e­sis of retinal degen­er­a­tion in geographic atrophy, and has the potential to address other ocular diseases. We are excited to develop gene therapies that precisely target this pathway, in col­lab­o­ra­tion with academic partners who have been at the forefront of char­ac­ter­iz­ing the biology underlying these diseases.”

The complement system plays a crucial role in the body’s innate immune system by enhancing its ability to clear pathogens and damaged cells, and regulating inflam­ma­to­ry immune responses through complement control proteins. Dys­reg­u­la­tion and hyper­ac­tiv­i­ty of the complement system is associated with the onset and progression of serious inflam­ma­to­ry diseases, including geographic atrophy and other ocular conditions. Through this agreement, Kriya is advancing gene therapies that are designed to durably express engineered molecules that selectively reduce complement hyper­ac­tiv­i­ty at the site of pathology following one-time administration.

“Geographic atrophy due to age-related macular degen­er­a­tion is a devastating disease with a profound impact on patients, as there are no approved treatments for the irre­versible loss of central vision that often occur,” said Peter K. Kaiser, M.D., Professor of Oph­thal­mol­o­gy, Cole Eye Institute, Cleveland Clinic. ​“Recent advances in complement inhibitor therapies have provided important additional evidence that targeting complement holds great promise in treating geographic atrophy. I am excited by the potential of restoring balance to the complement system with a one-time gene therapy that can deliver a meaningful long-term solution and a major advancement in the field of retinal disease.”

“By targeting the inhibition of complement proteins directly involved in complement activation, our approach has the potential to deliver a selective and profound biological effect,” said Dr. Bärbel Rohrer, Ph.D., Professor of Oph­thal­mol­o­gy at the Medical University of South Carolina, and co-inventor of the technology. ​“After having confirmed the potential of this gene therapy strategy in mouse models of age-related macular degen­er­a­tion, we are very excited to take the next step towards a clinical application for patients with geographic atrophy by partnering with Kriya, a leader in the development of novel gene therapies.”

About Kriya

Kriya is a fully integrated company pioneering novel tech­nolo­gies and ther­a­peu­tics in gene therapy. The company aims to rev­o­lu­tion­ize how gene therapies are designed, developed, and man­u­fac­tured, improving speed to market, and delivering significant reductions in cost. Kriya is organized into four principal business units: Kriya Tech­nolo­gies™, Kriya Ther­a­peu­tics™, Kriya R&D™, and Kriya Man­u­fac­tur­ing™. The company is advancing a deep and diversified pipeline of innovative gene therapies in multiple therapeutic area divisions, with current pipeline programs in oph­thal­mol­o­gy, oncology, rare disease, and chronic disease. Kriya was founded by pioneers in the bio­phar­ma­ceu­ti­cal industry and is backed by leading life sciences and technology investors. The company has core operations in Silicon Valley, California and Research Triangle Park, North Carolina. For more information, please visit www​.kriyatx​.com and follow on LinkedIn.

Contact
Danielle Cantey
Canale Com­mu­ni­ca­tions
danielle.​cantey@​canalecomm.​com
(619) 826‑4657